Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DR26FCRG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,553
Award facts
- Contract value 100% obligated
- $42,553.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on November 4, 2025, for the supply of Xtandi 40 mg tablets (120-count units) valued at $42,553.40 under firm fixed-price terms. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order will be performed at the vendor's location in Park Ridge, IL with an ultimate completion date of November 5, 2025.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The PPV-G GEN V contract authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. As an approved prime vendor contractor under this initiative, DMS Pharmaceutical Group supplies specialized oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals critical to the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCRG8?
SPE2DR26FCRG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FCRG8 worth?
The government has obligated $42,553 on SPE2DR26FCRG8.
Is contract SPE2DR26FCRG8 an order under another contract?
Yes. SPE2DR26FCRG8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRG8 competed?
The extent of competition for SPE2DR26FCRG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award